{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:20:41Z","timestamp":1793118041333,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2001,2,1]],"date-time":"2001-02-01T00:00:00Z","timestamp":980985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2001,2,1]],"date-time":"2001-02-01T00:00:00Z","timestamp":980985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2001,2]]},"DOI":"10.1007\/s11934-001-0027-7","type":"journal-article","created":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T19:40:36Z","timestamp":1181072436000},"page":"62-69","source":"Crossref","is-referenced-by-count":31,"title":["Immunotherapy for bladder cancer"],"prefix":"10.1007","volume":"2","author":[{"given":"Ashish M.","family":"Kamat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald L.","family":"Lamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"27_CR1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0094-0143(21)00412-2","volume":"19","author":"JY Ro","year":"1992","unstructured":"Ro JY, Staerkel GA, Ayala Ag: Cytologic and histologic features of superficial bladder cancer (review). J Urol Clin North Am 1992, 19:435\u2013449.","journal-title":"J Urol Clin North Am"},{"key":"27_CR2","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0022-5347(17)51695-X","volume":"130","author":"NM Heney","year":"1983","unstructured":"Heney NM, Ahmed S, Flanagan MJ, et al.: Superficial bladder cancer: progression and recurrence. J Urol 1983, 130:1083\u20131086.","journal-title":"J Urol"},{"key":"27_CR3","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1046\/j.1464-410X.1997.00431.x","volume":"80","author":"HW Herr","year":"1997","unstructured":"Herr HW: Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 1997, 80:762\u2013765.","journal-title":"Br J Urol"},{"key":"27_CR4","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1464-410X.1991.tb15355.x","volume":"68","author":"J Vicente","year":"1991","unstructured":"Vicente J, Laguna MP, Duarte D, et al.: Carcinoma in situ as a prognostic factor for G3pT1 bladder tumours. Br J Urol 1991, 68:380\u2013382.","journal-title":"Br J Urol"},{"key":"27_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1464-410X.1993.tb16274.x","volume":"72","author":"PD Abel","year":"1993","unstructured":"Abel PD: Follow-up of patients with \u201csuperficial\u201d transitional cell carcinoma of the bladder: the case for a change in policy. Br J Urol 1993, 72:135\u2013142.","journal-title":"Br J Urol"},{"key":"27_CR6","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/S0090-4295(99)80481-6","volume":"47","author":"J Palou","year":"1996","unstructured":"Palou J, Xavier B, Laguna P, et al.: In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guerin therapy without previous transurethral resection of the prostate. Urology 1996, 47:482\u2013484.","journal-title":"Urology"},{"key":"27_CR7","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","volume":"325","author":"DL Lamm","year":"1991","unstructured":"Lamm DL, Blumenstein BA, Crawford ED, et al.: A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Gu\u00e9rin for transitional cell carcinoma of the bladder. N Engl J Med 1991, 325:1205\u20131209.","journal-title":"N Engl J Med"},{"key":"27_CR8","first-page":"35","volume-title":"BCG Vaccine: Tuberculosis-Cancer","author":"C Guerin","year":"1980","unstructured":"Guerin C: The history of BCG. In BCG Vaccine: Tuberculosis-Cancer, edn 2. Edited by Rosenthal SR. Littleton, MA: PSG Publishisng; 1980:35.","edition":"edn 2"},{"key":"27_CR9","first-page":"97","volume":"9","author":"R Pearl","year":"1929","unstructured":"Pearl R: Cancer and tuberculosis. Proc Natl Acad Sci 1929, 9:97.","journal-title":"Proc Natl Acad Sci"},{"key":"27_CR10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW: Intracavitary bacillus Calmette-Gu\u00e9rin in the treatment of superficial bladder tumors. J Urol 1976, 116:180\u2013183.","journal-title":"J Urol"},{"key":"27_CR11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","volume":"124","author":"DL Lamm","year":"1980","unstructured":"Lamm DL, Thor DE, Harris SC, et al.: Bacillus Calmette-Gu\u00e9rin immunotherapy of superficial bladder cancer. J Urol 1980, 124:38\u201340.","journal-title":"J Urol"},{"key":"27_CR12","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S0022-5347(17)38622-6","volume":"145","author":"MJ Becich","year":"1991","unstructured":"Becich MJ, Carroll S, Ratliff TL: Internalization of Bacille Calmette-Gu\u00e9rin by bladder tumor cells. J Urol 1991, 145:1316\u20131324.","journal-title":"J Urol"},{"key":"27_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/BF00184040","volume":"9","author":"TL Ratliff","year":"1991","unstructured":"Ratliff TL, Hudson MA, Catalona WJ: Strategy for improving therapy of superficial bladder cancer. World J Urol 1991, 9:95\u201399.","journal-title":"World J Urol"},{"key":"27_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/BF00632180","volume":"3","author":"A Morales","year":"1986","unstructured":"Morales A, Nickel JC. Immunotherapy of superficial bladder cancer with BCG. World J Urol 1986, 3:209\u2013214.","journal-title":"World J Urol"},{"key":"27_CR15","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S0022-5347(17)36774-5","volume":"148","author":"RJ Garden","year":"1992","unstructured":"Garden RJ, Liu BCS, Redwood SM, et al.: Bacillus Calmette-Gu\u00e9rin abrogates in vitro invasion and motility of human bladder tumor cells via fibronectin interaction. J Urol 1992, 148:900\u2013905.","journal-title":"J Urol"},{"key":"27_CR16","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/S0022-5347(17)39741-0","volume":"144","author":"MA Hudson","year":"1990","unstructured":"Hudson MA, Yuan JJ, Catalona WJ, Ratliff TL: Adverse impact of fibrin clot inhibitors on intravesical Bacillus Calmette-Gu\u00e9rin therapy for superficial bladder tumors. J Urol 1990, 144:1362\u20131364.","journal-title":"J Urol"},{"key":"27_CR17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0022-5347(17)43909-7","volume":"137","author":"TL Ratliff","year":"1987","unstructured":"Ratliff TL, Gillen DP, Catalona WJ: Requirement of thymus dependent immune response for BCG mediated anitumor activity. J Urol 1987, 137:155\u2013159.","journal-title":"J Urol"},{"key":"27_CR18","first-page":"143","volume":"651","author":"M Davies","year":"1982","unstructured":"Davies M: Bacillus Calmette-Gu\u00e9rin as an antitumor agent. The interaction with cells of the mammalian immune system. Biochem Biophys Acta 1982, 651:143\u2013147.","journal-title":"Biochem Biophys Acta"},{"key":"27_CR19","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0022-5347(17)45142-1","volume":"136","author":"EO Haaff","year":"1986","unstructured":"Haaff EO, Catalona WJ, Ratliff TL: Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 1986, 136:970\u2013974.","journal-title":"J Urol"},{"key":"27_CR20","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/1097-0142(19830815)52:4<667::AID-CNCR2820520417>3.0.CO;2-C","volume":"52","author":"A Morales","year":"1983","unstructured":"Morales A, Ottenhof PC: Clinical application of a whole blood assay for human natural killer (NK) cell activity. Cancer 1983, 52:667\u2013670.","journal-title":"Cancer"},{"key":"27_CR21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0022-5347(17)52736-6","volume":"128","author":"SA Brosman","year":"1992","unstructured":"Brosman SA: Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 1992, 128:27.","journal-title":"J Urol"},{"key":"27_CR22","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.1998.545","volume":"78","author":"OT Jansson","year":"1998","unstructured":"Jansson OT, Morcos E, Brundin L, et al.: The role of nitric oxide in bacillus Calmette-Guerin mediated antitumour effects in human bladder cancer. Br J Cancer 1998, 78:588\u2013592.","journal-title":"Br J Cancer"},{"key":"27_CR23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0022-5347(17)46972-2","volume":"134","author":"DL Lamm","year":"1985","unstructured":"Lamm DL: Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder cancer. J Urol 1985,134:40\u201347.","journal-title":"J Urol"},{"key":"27_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0090-4295(85)90525-4","volume":"25","author":"HW Herr","year":"1985","unstructured":"Herr HW, Pinsky CM, Whitmore WF Jr, et al.: Experience with intravesical bacillus Calmette-Guerin therapy of superficial bladder tumors. Urology 1985, 25:119\u2013123.","journal-title":"Urology"},{"key":"27_CR25","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.1988.6.9.1450","volume":"6","author":"HW Herr","year":"1988","unstructured":"Herr HW, Laudone VP, Badalament RA, et al.: Bacillus Calmette-Gu\u00e9rin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988, 6:1450\u20131455.","journal-title":"J Clin Oncol"},{"key":"27_CR26","first-page":"525","volume-title":"The Urologic Clinics of North America","author":"HW Herr","year":"1991","unstructured":"Herr HW: Transurethral resection and intravesical therapy of superficial bladder tumors. In The Urologic Clinics of North America. Edited by Fair WR. Philadelphia: WB Saunders; 1991:525\u2013528."},{"key":"27_CR27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0022-5347(17)37707-8","volume":"146","author":"F Pagano","year":"1991","unstructured":"Pagano F, Bassi P, Milani C, et al.: Low dose BCG regimen in superficial bladder cancer therapy: is it effective?\n                           J Urol 1991, 146:32\u201335.","journal-title":"J Urol"},{"key":"27_CR28","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0022-5347(17)36197-9","volume":"149","author":"MD Melekos","year":"1993","unstructured":"Melekos MD, Chionis H, Pantazakos A, et al.: Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule. J Urol 1993, 149:744\u2013748.","journal-title":"J Urol"},{"key":"27_CR29","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S0022-5347(01)65673-8","volume":"156","author":"S Krege","year":"1996","unstructured":"Krege S, Giani G, Meyer R, et al.: A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. J Urol 1996, 156:962\u2013926.","journal-title":"J Urol"},{"key":"27_CR30","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S0090-4295(99)00591-9","volume":"55","author":"M Brake","year":"2000","unstructured":"Brake M, Loertzer H, Horsch R, Keller H: Long-term results of intravesical bacillus Calmette-Guerin therapy for stage T1 superficial bladder cancer. Urology 2000, 55:673\u2013678.","journal-title":"Urology"},{"key":"27_CR31","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0022-5347(17)39546-0","volume":"144","author":"DE Coplen","year":"1990","unstructured":"Coplen DE, Marcus MD, Myers JA, et al.: Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. J Urol 1990, 144:652\u2013657.","journal-title":"J Urol"},{"key":"27_CR32","first-page":"573","volume-title":"The Urologic Clinics of North America","author":"DL Lamm","year":"1992","unstructured":"Lamm DL. Long term results of intravesical therapy for superficial bladder cancer. In The Urologic Clinics of North America. Edited by Lamm DL. Philadelphia: WB Saunders; 1992:573\u2013580."},{"key":"27_CR33","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/0090-4295(91)80166-5","volume":"38","author":"R De Jager","year":"1991","unstructured":"De Jager R, Guinan P, Lamm D, et al.: Long term complete remission in bladder carcinoma in situ with intravesical Tice Bacillus Calmette Guerin\u2014overview analysis of six pahse II clinical trials. Urology 1991, 38:507\u2013514.","journal-title":"Urology"},{"key":"27_CR34","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/1097-0142(19950115)75:2<552::AID-CNCR2820750219>3.0.CO;2-H","volume":"75","author":"H Akaza","year":"1995","unstructured":"Akaza H, Hinotsu S, Aso Y, et al.: Bacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer 1995, 75:552\u2013559.","journal-title":"Cancer"},{"key":"27_CR35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1464-410X.1998.00720.x","volume":"82","author":"NA Mungan","year":"1998","unstructured":"Mungan NA, Witjes JA: Bacille Calmette-Guerin in superficial transitional cell carcinoma. Br J Urol 1998, 82:213\u2013223.","journal-title":"Br J Urol"},{"key":"27_CR36","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1159\/000019635","volume":"33","author":"A Orsola","year":"1998","unstructured":"Orsola A, Palou J, Xavier B, et al.: Primary bladder carcinoma in situ: assessment of early BCG response as a prognostic factor. Eur Urol 1998, 33:457\u2013463.","journal-title":"Eur Urol"},{"key":"27_CR37","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0022-5347(17)37317-2","volume":"147","author":"EA Klein","year":"1992","unstructured":"Klein EA, Rogatko A, Herr HW: Management of local bacillus Calmette-Guerin failures in superficial bladder cancer. J Urol 1992, 147:601\u2013605.","journal-title":"J Urol"},{"key":"27_CR38","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S0090-4295(99)80418-X","volume":"47","author":"RS Rosenbaum","year":"1996","unstructured":"Rosenbaum RS, Park MC, Fleischmann J: Intravesical bacille Calmette-Guerin therapy for muscle invasive bladder cancer. Urology 1996, 47:208\u2013211.","journal-title":"Urology"},{"key":"27_CR39","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0022-5347(17)38439-2","volume":"145","author":"DL Lamm","year":"1991","unstructured":"Lamm DL, DeHaven JI, Shriver J, Sarosdy MF: Percutaneous and intravesical prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer. J Urol 1991, 145:738\u2013740.","journal-title":"J Urol"},{"key":"27_CR40","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0022-5347(17)38379-9","volume":"145","author":"CA D\u2019Ancona","year":"1991","unstructured":"D\u2019Ancona CA, Netto Jr NR, Claro JA, Ikari O: Oral or intravesical bacillus Calmette-Guerin immunoprophylaxis in bladder carcinoma. J Urol 1991, 145:498\u2013501.","journal-title":"J Urol"},{"key":"27_CR41","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0022-5347(17)55150-2","volume":"125","author":"A Morales","year":"1981","unstructured":"Morales A, Ottenhof P, Emerson L: Treatment of residual, non-infiltrating bladder cancer with bacillus Calmette-Guerin. J Urol 1981, 125:649\u2013651.","journal-title":"J Urol"},{"key":"27_CR42","first-page":"239","volume":"17","author":"Ortiz D Corti","year":"1993","unstructured":"Corti Ortiz D, Rivera Garay P, Aviles Jasse J, et al.: Prophylaxis of superficial bladder cancer with 1 mg of intravesical BCG: comparision with other doses. Actas Urol Esp 1993, 17:239\u2013242.","journal-title":"Actas Urol Esp"},{"key":"27_CR43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0022-5347(17)46976-X","volume":"134","author":"DR Kelley","year":"1985","unstructured":"Kelley DR, Ratliff TL, Catalona WJ, et al.: Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results. J Urol 1985, 134:48\u201353.","journal-title":"J Urol"},{"key":"27_CR44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000282516","volume":"51","author":"JA Witjes","year":"1993","unstructured":"Witjes JA, Fransen MPH, van der Meijden APM, et al.: Use of maintenance intravesical Bacillus Calmette-Guerin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Urol Int 1993, 51:67\u201372.","journal-title":"Urol Int"},{"key":"27_CR45","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0022-5347(17)42722-4","volume":"139","author":"LR Kavoussi","year":"1988","unstructured":"Kavoussi LR, Torrence RJ, Gillen DP, et al.: Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors. J Urol 1988, 139:935\u2013940.","journal-title":"J Urol"},{"key":"27_CR46","first-page":"32","volume":"80(suppl","author":"J Palou","year":"1997","unstructured":"Palou J, Laguna P, Algaba F, et al.: High grade superficial transitional cell cercinoma of the bladder and\/or CIS treatment with BCG: control vs maintenance treatment. Br J Urol 1997, 80(suppl):32.","journal-title":"Br J Urol"},{"key":"27_CR47","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0022-5347(01)65110-3","volume":"157","author":"DL Lamm","year":"1997","unstructured":"Lamm DL, Blumenstein B, Sarsody M, et al.: Significant long-term patient benefits with BCG maintenance therapy:a South West Oncology Group study. J Urol 1997, 157:213.","journal-title":"J Urol"},{"key":"27_CR48","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD, et al.: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1, and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000, 163:1124\u20131129. A much awaited follow-up on the often quoted results previously only found in abstract form. This paper validates Lamm\u2019s 6+3 protocol and shows a significant advantage of maintenance BCG therapy.","journal-title":"J Urol"},{"key":"27_CR49","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","volume":"147","author":"DL Lamm","year":"1992","unstructured":"Lamm DL, van der Meijden APM, Morales A, et al.: Incidence and treatment of complications of Bacillus Calmette-Gu\u00e9rin intravesical therapy in superficial bladder cancer. J Urol 1992, 147:596\u2013600.","journal-title":"J Urol"},{"key":"27_CR50","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0022-5347(17)36973-2","volume":"148","author":"EC De Boer","year":"1992","unstructured":"De Boer EC, Steerenberg PA, van der Meijden APM, et al.: Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig. J Urol 1992, 148:1577\u20131582.","journal-title":"J Urol"},{"key":"27_CR51","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0022-5347(17)37369-X","volume":"147","author":"JI DeHaven","year":"1992","unstructured":"DeHaven JI, Traynelis C, Riggs DR, et al.: Antibiotic and steroid therapy of massive systemic Bacillus Calmette-Gu\u00e9rin toxicity. J Urol 1992, 147:738\u2013742.","journal-title":"J Urol"},{"key":"27_CR52","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000464019","volume":"17","author":"A Bohle","year":"1990","unstructured":"Bohle A, Schuller J, Knipper A, Hofstetter A: Bacillus Calmette-Guerin treatment and vesicorenal reflux. Eur Urol 1990, 17:125\u2013128.","journal-title":"Eur Urol"},{"key":"27_CR53","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0022-5347(17)49877-6","volume":"132","author":"EC Borden","year":"1984","unstructured":"Borden EC, Groveman DS, Nasu T, et al.: Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. J Urol 1984, 132:800\u2013803.","journal-title":"J Urol"},{"key":"27_CR54","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1200\/JCO.1988.6.3.476","volume":"6","author":"FM Torti","year":"1988","unstructured":"Torti FM, Shortliffe LD, Williams RD, et al.: Alpha-Interferon in superficial bladder cancer: a northern California oncology group study. J Clin Oncol 1988, 6:476\u2013483.","journal-title":"J Clin Oncol"},{"key":"27_CR55","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0022-5347(17)39547-2","volume":"144","author":"R Glashan","year":"1990","unstructured":"Glashan R: A randomized controlled study of intravesical a-2b-interferon in carcinoma in situ of the bladder. J Urol 1990, 144:658\u2013661.","journal-title":"J Urol"},{"key":"27_CR56","first-page":"133","volume":"33","author":"T Kalble","year":"1994","unstructured":"Kalble T, Beer M, Mendoza E, et al.: BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study. Urologe A 1994, 33:133\u2013137.","journal-title":"Urologe A"},{"key":"27_CR57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1994.12.1.7","volume":"12","author":"F Boccardo","year":"1994","unstructured":"Boccardo F, Cannata D, Rubagotti A, et al.: Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. J Clin Oncol 1994, 12:7\u201313.","journal-title":"J Clin Oncol"},{"key":"27_CR58","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0090-4295(97)00303-8","volume":"50","author":"JF Jimenez-Cruz","year":"1997","unstructured":"Jimenez-Cruz JF, Vera-Donoso CD, Leiva O, et al.: Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guerin and interferon-alpha. Urology 1997, 50:529\u2013535.","journal-title":"Urology"},{"key":"27_CR59","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0022-5347(01)61609-4","volume":"161","author":"P Rajala","year":"1999","unstructured":"Rajala P, Liukkonen T, Raitanen M, et al.: Transurethral resection with perioperative instilation on interferonalpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study\u2014Finnbladder III. J Urol 1999, 161:1133\u20131135. A well-designed randomized trial with a large number of patients that shows a benefit for intravesical chemotherapy after TURBT but not for immunotherapy. This is in accordance with the mechanisms of action of both modalities.","journal-title":"J Urol"},{"key":"27_CR60","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0022-5347(17)37199-9","volume":"147","author":"DR Riggs","year":"1992","unstructured":"Riggs DR, Tarry WF, DeHaven JI, et al.: Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy. J Urol 1992, 147:212\u2013214.","journal-title":"J Urol"},{"key":"27_CR61","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0090-4295(96)00375-5","volume":"48","author":"P Stricker","year":"1996","unstructured":"Stricker P, Pryor K, Nicholson T, et al.: Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology 1996, 48:957\u2013961.","journal-title":"Urology"},{"key":"27_CR62","first-page":"257","volume":"67","author":"E Bercovich","year":"1995","unstructured":"Bercovich E, Deriu M, Manferrari F, Irianni G: BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder. Arch Ital Urol Androl 1995, 67:257\u2013260.","journal-title":"Arch Ital Urol Androl"},{"key":"27_CR63","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0094-0143(05)70245-7","volume":"27","author":"DH Brown","year":"2000","unstructured":"Brown DH, Wagner TT, Bahnson RR: Interferons and bladder cancer. Urol Clin North Am 2000, 27:171\u2013178. A comprehensive review of the role of interferons in bladder cancer.","journal-title":"Urol Clin North Am"},{"key":"27_CR64","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/BF00295189","volume":"21","author":"DL Lamm","year":"1993","unstructured":"Lamm DL, DeHaven JI, Riggs DR, et al.: Keyhole limpet hemocyanin immunotherapy of murine bladder cancer. Urol Res 1993, 21:33\u201337.","journal-title":"Urol Res"},{"key":"27_CR65","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0022-5347(17)42610-3","volume":"139","author":"CD Jurincic","year":"1988","unstructured":"Jurincic CD, Engelmann U, Gasch J, Klippel KF: Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study. J Urol 1988, 139:723\u2013726.","journal-title":"J Urol"},{"key":"27_CR66","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000052391","volume":"37(suppl","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Dehaven JI, Riggs DR: Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies. Eur Urol 2000, 37(suppl):41\u201344.","journal-title":"Eur Urol"},{"key":"27_CR67","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0090-4295(96)90059-X","volume":"48","author":"MF Sardosy","year":"1996","unstructured":"Sardosy MF, Lowe BA, Schellhammer PF, et al.: Bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. Urology 1996, 48:21\u201327.","journal-title":"Urology"},{"key":"27_CR68","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1159\/000020051","volume":"36","author":"WP Witjes","year":"1999","unstructured":"Witjes WP, Konig M, Boeminghaus FP, et al.: Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group. Eur Urol 1999, 36:576\u2013581.","journal-title":"Eur Urol"},{"key":"27_CR69","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1097\/00005392-199804000-00021","volume":"159","author":"W Den Otter","year":"1998","unstructured":"Den OtterW, Dobrowolski Z, Bugajski A, et al.: Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J Urol 1998, 159:1183\u20131186.","journal-title":"J Urol"},{"key":"27_CR70","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/S0022-5347(05)67677-X","volume":"163","author":"M Eto","year":"2000","unstructured":"Eto M, Harada M, Tamada K, et al.: Antitumor activity of interleukin-12 against murine bladder cancer. J Urol 2000, 163:1549\u20131552.","journal-title":"J Urol"},{"key":"27_CR71","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0094-0143(05)70242-1","volume":"27","author":"SK Clinton","year":"2000","unstructured":"Clinton SK, Canto E, O\u2019Donnell MA: Interleukin-12. Opportunities for the treatment of bladder cancer. Urol Clin North Am 2000, 27:147\u2013155.","journal-title":"Urol Clin North Am"},{"key":"27_CR72","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0022-5347(17)45031-2","volume":"136","author":"BHS Lau","year":"1986","unstructured":"Lau BHS, Woolley JL, Marsh CL, et al.: Superiority of intralesional immunotherapy with Corynebacterium parvum and Allium sativum in the control of murine transitional cell carcinoma. J Urol 1986, 136:701.","journal-title":"J Urol"},{"key":"27_CR73","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1002\/(SICI)1097-0142(19970515)79:10<1987::AID-CNCR21>3.0.CO;2-Q","volume":"79","author":"DR Riggs","year":"1997","unstructured":"Riggs DR, DeHaven JI, Lamm DL: Allium sativum (garlic) treatment for murine transitional cell carcinoma. Cancer 1997, 79:1987.","journal-title":"Cancer"},{"key":"27_CR74","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/S0022-5347(05)68793-9","volume":"161","author":"AM Kamat","year":"1999","unstructured":"Kamat AM, Lamm DL: Chemoprevention of urologic cancer. J Urol 1999, 161:1748\u20131760.","journal-title":"J Urol"},{"key":"27_CR75","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0022-5347(17)34863-2","volume":"151","author":"DL Lamm","year":"1994","unstructured":"Lamm DL, Riggs DR, Shriver JS, et al.: Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 1994, 151:21.","journal-title":"J Urol"},{"key":"27_CR76","unstructured":"Traynelis CL, Lamm DL: Current status of intravesical therapy for bladder cancer. In Urology Annual, vol 8. Edited by Rous SN. WW Norton; 1994:113\u2013143."}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-001-0027-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-001-0027-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-001-0027-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-001-0027-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T11:06:06Z","timestamp":1652612766000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11934-001-0027-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,2]]}},"alternative-id":["27"],"URL":"https:\/\/doi.org\/10.1007\/s11934-001-0027-7","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,2]]}}}